Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ - independent resolution of treated-turmors and CD4+ -dependent systemic and memory responses
Targeting interleukin-2 (IL-2) and/or agonist anti-CD40 antibody (Ab) into tumors represents an effective vaccination strategy that avoids systemic toxicity and resolves treated-site tumors. Here, we examined IL-2 and/or anti-CD40 Ab-driven local versus systemic T cell function and the installation...
| Main Authors: | , |
|---|---|
| Format: | Journal Article |
| Published: |
Springer
2012
|
| Subjects: | |
| Online Access: | http://link.springer.de/link/service/journals/00262/index.htm http://hdl.handle.net/20.500.11937/49275 |